Organon (MEX:OGN) NonCurrent Deferred Liabilities: MXN890 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:OGN Organon & Co MEX:OGN
73 GF Score
Price MXN225.00
GF Value MXN218.45
! 11 Warning Signs
View Full Analysis

What is Organon NonCurrent Deferred Liabilities?

Organon MEX:OGN 73 NonCurrent Deferred Liabilities is MXN890 Mil as of Jun. 2026. GuruFocus rates MEX:OGN with a GF Score™ of 73/100 and a GF Value™ of MXN218.45. The stock has 11 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Organon's non-current deferred liabilities for the quarter that ended in Jun. 2026 was MXN890 Mil.

Organon NonCurrent Deferred Liabilities Related Terms

Organon NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Organon's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organon NonCurrent Deferred Liabilities Chart

Organon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 82.06 370.42 797.79 1,543.32 1,026.33

Organon Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,299.22 1,137.34 1,026.33 1,009.83 889.90
MEX:OGN
73GF Score
Organon & Co MEX:OGN
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of MXN890 Mil mean?
Organon (MEX:OGN) has a NonCurrent Deferred Liabilities of MXN890 Mil as of Jun. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Organon and its competitors.
Is Organon's NonCurrent Deferred Liabilities too high?
Organon's current NonCurrent Deferred Liabilities is MXN890 Mil. Overall, Organon has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Organon's NonCurrent Deferred Liabilities compare to AMRN and SCLX?
Organon's NonCurrent Deferred Liabilities of MXN890 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Organon and its competitors. Organon's current NonCurrent Deferred Liabilities is MXN890 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Organon (MEX:OGN) has a current NonCurrent Deferred Liabilities of MXN890 Mil. The stock's GF Value™ is MXN218.45, compared to a current price of MXN225.00 — trading 3% above its estimated fair value. The current NonCurrent Deferred Liabilities is MXN890 Mil. Organon's overall GF Score™ is 73/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Organon (MEX:OGN), the current NonCurrent Deferred Liabilities is MXN890 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organon (MEX:OGN) Overvalued in 2026?

Based on GuruFocus' analysis, Organon stock appears to be overvalued. The current stock price of MXN225.00 is trading 3% above its estimated GF Value™ of MXN218.45.

Key valuation signals for MEX:OGN:

  • NonCurrent Deferred Liabilities: MXN890 Mil
  • GF Value™: MXN218.45 vs. price of MXN225.00 (3% above fair value)
  • GF Score™: 73/100 with 11 warning signs

No single metric tells the full story. See the MEX:OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organon Business Description

Address 30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
73GF Score

Get the complete analysis for MEX:OGN

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN225.00
Price
MXN218.45
GF Value